Increased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases

Journal of Internal Medicine

Volumn 278, Issue 3, 2015, Pages 264-276

  Ambati, A ^a,b   Poiret, T ^a   Svahn, B M ^b   Valentini, D ^b   Khademi, M ^a   Kockum, I ^a   Lima, I ^a   Arnheim Dahlstrom L ^a   Lamb, F ^a   Fink, K ^a   Meng, Q ^a   Kumar, A ^c   Rane, L ^a   Olsson, T ^a   Maeurer, M ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Streptococcus; Interferon gamma; Narcolepsy; Pandemrix; Streptolysin; T cells

Indexed keywords

ANTISTREPTOLYSIN; GAMMA INTERFERON; HLA DQB1 ANTIGEN; INFLUENZA VACCINE; INTERLEUKIN 17; INTERLEUKIN 2; STREPTODORNASE; TUMOR NECROSIS FACTOR ALPHA; INTERFERON GAMMA (1-39); PEPTIDE FRAGMENT; STREPTODORNASE PLUS STREPTOKINASE;

ANIMAL TISSUE; ARTICLE; BLOOD; CELL LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HLA SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NARCOLEPSY; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RAT; SEROTYPE; STIMULATION; STREPTOCOCCUS GROUP A; SWEDISH CITIZEN; T LYMPHOCYTE; ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; CHILD; ENZYMOLOGY; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; SEROTYPING; STREPTOCOCCUS AGALACTIAE; SWEDEN;

ADOLESCENT; ADULT; AGED; ANTISTREPTOLYSIN; CHILD; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NARCOLEPSY; PEPTIDE FRAGMENTS; SEROTYPING; STREPTOCOCCUS AGALACTIAE; STREPTODORNASE AND STREPTOKINASE; SWEDEN;

EID: 84938739764     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12355     Document Type: Article

References (87)

1. Daniels LE. Narcolepsy. Medicine 1934; 13: 122-3.
2. Mignot E, Lin L, Rogers W et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001; 68: 686-99.
3. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 2014; 13: 600-13.
4. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 1012-20.
5. Mignot E, Lin X, Arrigoni J et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994; 17: S60-7.
6. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39-40.
7. Thannickal TC, Moore RY, Nienhuis R et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
8. Peyron C, Faraco J, Rogers W et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7.
9. Swedish Medical Product Agency (MPA). Registry study confirms increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents and shows an increased risk in young adults. 2013. Available from: http://www.lakemedelsverket.se/english/All-news/NYHETER-2013/Registrystudy-confirms-increased-risk-of-narcolepsy-after-vaccination-with-Pandemrix-inchildren-and-adolescents-and-shows-an-increased-risk-in-young-adults/.
10. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012; 7: e33723.
11. Dauvilliers Y, Montplaisir J, Cochen V et al. Post-H1N1 Narcolepsy-Cataplexy. Sleep 2010; 33: 1428-30.
12. THL, F.N.I.f.H.a.W. National Institute for Health and Welfare recommends discontinuation of Pandemrix vaccinations, 2010.
13. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012; 7: e33536.
14. Wijnans L, Lecomte C, De Vries C et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31: 1246-54.
15. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013; 80: 1315-21.
16. Heier MS, Gautvik KM, Wannag E et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Medi 2013; 14: 867-71.
17. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014; 14: 227-38.
18. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014; 275: 172-90.
19. Cvetkovic-Lopes V, Bayer L, Dorsaz S et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010; 120: 713-9.
20. Kawashima M, Lin L, Tanaka S et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 2010; 33: 869-74.
21. Deloumeau A, Bayard S, Coquerel Q et al. Increased immune complexes of hypocretin autoantibodies in narcolepsy. PLoS ONE 2010; 5: e13320.
22. Hallmayer J, Faraco J, Lin L et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009; 41: 708-11.
23. Han F, Lin L, Li J et al. HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens 2012; 80: 328-35.
24. Kornum BR, Kawashima M, Faraco J et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011; 43: 66-71.
25. Hinze-Selch D, Wetter TC, Zhang Y et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998; 50: 1149-52.
26. Okun ML, Giese S, Lin L, Einen M, Mignot E, Coussons-Read ME. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun 2004; 18: 326-32.
27. Himmerich H, Beitinger PA, Fulda S et al. Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. Arch Intern Med 2006; 166: 1739-43.
28. Kockum I, Sanjeevi CB, Eastman S, Landin-Olsson M, Dahlquist G, Lernmark A. Population analysis of protection by HLA-DR and DQ genes from insulin-dependent diabetes mellitus in Swedish children with insulin-dependent diabetes and controls. Eur J Immunogenet 1995; 22: 443-65.
29. Koepsell TD, Longstreth WT, Ton TGN. Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population-based case-control study in genetically predisposed people. J Sleep Res 2010; 19: 80-6.
30. Aran A, Lin L, Nevsimalova S et al. Elevated Anti-Streptococcal Antibodies in Patients with Recent Narcolepsy Onset. Sleep 2009; 32: 979-83.
31. Billiard M, Laaberki C, Reygrobellet C, Seignalet J, Brissaud L, Besset A. Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 1989; 18: 201.
32. Montplaisir J, Poirier G, Lapierre O, Montplaisir S. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia. Sleep Res 1989; 18: 271.
33. Mueller-Eckhardt G, Meier-Ewart K, Schiefer HG. Is there an infectious origin of narcolepsy? Lancet 1990; 335: 424.
34. Han F, Lin L, Warby SC et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china. Ann Neurol 2011; 70: 410-7.
35. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997; 20: 620-9.
36. Alvarez-Corrales N, Ahmed RK, Rodriguez CA et al. Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-gamma and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras. BMC Infect Dis 2013; 13: 125.
37. Lagrelius M, Jones P, Franck K, Gaines H. Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytokine 2006; 33: 156-65.
38. Magalhaes I, Vudattu NK, Ahmed RK et al. High content cellular immune profiling reveals differences between rhesus monkeys and men. Immunology 2010; 131: 128-40.
39. Vera JF, Brenner LJ, Gerdemann U et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33: 305-15.
40. Johnson DR, Kaplan EL, Sramek J, Bicova R, Havlicek J, Motlova J. Laboratory diagnosis of group A streptococcal infections. Geneva: World Health Organization, 1997.
41. Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-14.
42. Reche PA, Reinherz EL. Prediction of peptide-MHC binding using profiles. Methods Mol Biol 2007; 409: 185-200.
43. Kumar N, Mohanty D. MODPROPEP: a program for knowledge-based modeling of protein-peptide complexes. Nucleic Acids Res 2007; 35(Web Server issue): W549-55.
44. Kumar A, Melis P, Genna V, Cocco E, Marrosu MG, Pieroni E. Antigenic peptide molecular recognition by the DRB1-DQB1 haplotype modulates multiple sclerosis susceptibility. Mol BioSyst 2014; 10: 2043-2054.
45. London N, Raveh B, Cohen E, Fathi G, Schueler-Furman O. Rosetta FlexPepDock web server-high resolution modeling of peptide-protein interactions. Nucleic Acids Res 2011; 39: W249-53.
46. Guilherme L, Kalil J, Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006; 39: 31-9.
47. Lancefield RC. The antigenic complex of streptococcus haemolyticus: I. demonstration of a type-specific substance in extracts of streptococcus haemolyticus. J Exp Med 1928; 47: 91-103.
48. Jones KF, Fischetti VA. The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J Exp Med 1988; 167: 1114-23.
49. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2: 285-314.
50. Beachey EH, Seyer JM, Dale JB, Simpson WA, Kang AH. Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature 1981; 292: 457-9.
51. Lancefield RC. Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med 1959; 110: 271-92.
52. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962; 89: 307-13.
53. Cunningham MW, Antone SM, Gulizia JM, McManus BM, Fischetti VA, Gauntt CJ. Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin. Proc Natl Acad Sci U S A 1992; 89: 1320-4.
54. Plazzi G, Pizza F, Palaia V et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011; 134: 3477-89.
55. Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995; 34: 307-11.
56. Swedo SE, Leonard HL, Schapiro MB et al. Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 1993; 91: 706-13.
57. Husby G, van de Rijn I, Zabriskie JB, Abdin ZH, Williams RC Jr. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144: 1094-110.
58. Swedo SE. Sydenham's chorea. A model for childhood autoimmune neuropsychiatric disorders. JAMA 1994; 272: 1788-91.
59. Pelin Z, Guilleminault C, Risch N, Grumet FC, Mignot E. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998; 51: 96-100.
60. Dale JB, Beachey EH. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med 1985; 162: 583-91.
61. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13: 470-511.
62. Dale JB, Beachey EH. Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins. J Exp Med 1987; 166: 1825-35.
63. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004; 138: 83-93.
64. Guilherme L, Oshiro SE, Fae KC et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001; 69: 5345-51.
65. Norrby-Teglund A, Norrby SR, Low DE. The treatment of severe group A streptococcal infections. Curr Infect Dis Rep 2003; 5: 28-37.
66. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992; 165: 879-85.
67. Sriskandan S, Cohen J. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am 1999; 13: 397-412.
68. Kappler J, Kotzin B, Herron L et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science 1989; 244: 811-3.
69. Tomai MA, Aelion JA, Dockter ME, Majumdar G, Spinella DG, Kotb M. T cell receptor V gene usage by human T cells stimulated with the superantigen streptococcal M protein. J Exp Med 1991; 174: 285-8.
70. Wang B, Schlievert PM, Gaber AO, Kotb M. Localization of an immunologically functional region of the streptococcal superantigen pepsin-extracted fragment of type 5 M protein. J Immunol 1993; 151: 1419-29.
71. Robinson JH, Case MC, Kehoe MA. Characterization of a conserved helper-T-cell epitope from group A Streptococcal M proteins. Infect Immun 1993; 61: 1062-8.
72. Fleischer B, Schmidt KH, Gerlach D, Kohler W. Separation of T-cell-stimulating activity from streptococcal M protein. Infect Immun 1992; 60: 1767-70.
73. Juvet SC, Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. J Mol Cell Biol 2012; 4: 48-58.
74. Cowley SC, Hamilton E, Frelinger JA, Su J, Forman J, Elkins KL. CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med 2005; 202: 309-19.
75. Crispin JC, Oukka M, Bayliss G et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761-6.
76. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004; 172: 3893-904.
77. Bergman P, Adori C, Vas S et al. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc Natl Acad Sci U S A 2014; 111: E3735-44.
78. Toussirot É, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008; 22: 883-96.
79. Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013; 2013: 535738.
80. Banwell B, Krupp L, Kennedy J et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6: 773-81.
81. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155-7.
82. Murali-Krishna K, Altman JD, Suresh M et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-87.
83. Ferri C, Zignego AL. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 2000; 12: 53-60.
84. Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein-Barr virus and multiple sclerosis. Mult Scler 2012; 18: 1204-8.
85. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985; 230: 1043-5.
86. Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998; 279: 1344-7.
87. Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001; 108: 311-8.